Abstract
Background Multimorbidity presents a growing public health challenge. While existing research has mainly focused on cross-sectional patterns of multimorbidity, there remains a need to better understand the longitudinal accumulation of diseases and the effects of important sociodemographic characteristics on the accumulation and progression of chronic conditions.
Methods and findings We use a spline-based parametric multistate modelling (MSM) framework for investigating the role of several sociodemographic characteristics such as ethnicity, deprivation, gender, and age on the rate of disease transitions along different pathways to multimorbidity accumulation. The model is highly flexible and permits a parallel estimation framework that scales well to very large datasets. Focusing on cardiometabolic, renal conditions and mental conditions, we analysed a dataset of about 13 million English electronic primary care records. Our results revealed complex interactions between temporal trajectories of multimorbidity and the sociodemographic factors, with effects that varied depending on the comorbidity status of the subject. These factors tended to have a larger impact on initial multimorbidity development while a smaller impact on later stages. Mental health as a comorbidity often strengthened the adverse effects of sociodemographic characteristics on disease accumulation.
Conclusion Our findings underscore the potential importance of earlier screening and intervention of chronic conditions, particular for mental health conditions, in the higher-risk populations. This may have important implications for the management of multimorbidity.
Competing Interest Statement
JB has previously received funding for unrelated work from F. Hoffmann-La Roche Ltd. KN reports grants from NIHR, MRC, Diabetes UK, Vifor, and AstraZeneca, and personal fees from Merck Sharp & Dohme, Sanofi, and Boehringer Ingelheim, outside of and unrelated to the submitted work. TM has previously received funding for unrelated work: from Cancer Research UK and from the Health Research Board (Ireland) for advisory board participation and travel. SJG received payment from Novo Nordisk, Napp and Astra Zeneca for lectures at 6 educational events over the last 3 years. Napp supported SJG's attendance at EASD 2018 and he received payment from Eli Lilly associated with membership of an independent data monitoring committee for a randomised trial of a medication to lower glucose. PK, SR and KN are co-investigators on the HDRUK grant titled Measuring & Understanding Multimorbidity using Routine Data in the UK (MUrMuR-UK). CY has received remuneration for unrelated consultancy services to F. Hoffmann-La Roche and Singula Bio. The remaining authors have no conflicts of interest.
Funding Statement
This work is funded by the MRC/NIHR grant MR/S027602/1 (BIRM-CAM). TM is supported by the National Institute for Health Research Collaboration Applied Research Collaboration West Midlands (NIHR ARC WM). KN is funded by a Health Data Research UK Fellowship. CY is funded by a UKRI Turing AI Fellowship (EP/V023233/2). JB was funded by MRC unit programme MC_UU_00002/5. CJ was funded by the Medical Research Council programme number MRC_MC_UU_00002/11. PK was funded by MRC unit programme MC_UU_00002/13. SR was funded by MRC unit programme MC_UU_00002/10. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Clinical Practice Research Datalink (CPRD) Research Database has ethics approval from the Health Research Authority to support research using anonymised patient data (East Midlands - Derby Research Ethics Committee, reference 21/EM/0265). Data was approved for this study by the CPRD Independent Scientific Advisory Committee (protocol 19_265).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The data were provided under license by the Clinical Practice Research Datalink (CPRD), and so are not publicly available. Access to CPRD data is subject to protocol approval via CPRD's Research Data Governance (RDG) Process.
